Rahul Gosain is a journalist who specializes in writing about oncology for Targeted Oncology. With a focus on the latest research and developments in the field, Rahul provides insightful articles on clinical trials, treatment options, and advancements in cancer care. His work aims to inform and educate healthcare professionals and patients alike.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Rahul's articles focus on scientific and healthcare-related topics, specifically in the field of oncology with a strong emphasis on breast cancer. His coverage tends to cite data and press releases frequently, indicating an evidence-based approach.
Based on this information, Rahul would likely be interested in pitches that provide insights into the latest advancements in breast cancer treatment, clinical trial results, or data analysis within the field of oncology. Expert commentary from researchers or professionals involved in developing new treatments or analyzing clinical trial data could be particularly appealing to him.
Given his wide-ranging coverage across various scientific and healthcare themes without specific geographic focus mentioned, it may benefit outreach efforts to offer international perspectives or research findings relevant to global audiences.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Rahul Gosain, Rohit Gosain
Along with the Oncology Brothers, Paola Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- metastatic breast cancer, particularly in patients with ESR1 mutations.
By: Rahul Gosain, Rohit Gosain
Along with the Oncology Brothers, Paoloa Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1m mutations at both the initial diagnosis of metastatic breast cancer (MBC) and at each subsequent progression using liquid biopsy assays.
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective estrogen receptor degraders (SERDs), including elacestrant, highlighting trials exploring its combination with other therapies and its potential in different patient populations.
By: Rahul Gosain, Rohit Gosain
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients with ESR1 mutations (ESR1m) who had been on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy for 12 months or longer, and shares her his perspectives on how these findings may influence the use of elacestrant in ER+/HER2–- metastatic breast cancer (MBC) and impact clinical practice for community oncologists.
Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring and management of adverse reactions effects (AEs) to elacestrant, emphasizing strategies to help patients remain on therapy while maximizing their quality of life.
Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and discusses the ongoing research into the prognostic significance of these co-occurring mutations in metastatic breast cancer.
By: Rohit Gosain, Benjamin P. Levy, Rahul Gosain
Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.
By: Rahul Gosain, Rohit Gosain
In a recent Treatment Algorithms with the Oncology Brothers program, Rohit Gosain, MD, Rahul Gosain, MD, and Shannon N.
By: Rohit Gosain, Rahul Gosain
Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.
By: Rahul Gosain, Rohit Gosain
Surgery followed by platinum-based chemotherapy may provide the most benefit for patients with ovarian cancer, according to a medical oncologist.
(833) 317-6278 